367 related articles for article (PubMed ID: 31848739)
1. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Chen J; Wang J; Lin H; Peng Y
Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
[TBL] [Abstract][Full Text] [Related]
3. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.
Jing Z; Rui Z; Binglan Z
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2313-2323. PubMed ID: 31278474
[TBL] [Abstract][Full Text] [Related]
4. Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Casadei-Gardini A; Vagheggini A; Gelsomino F; Spallanzani A; Ulivi P; Orsi G; Rovesti G; Andrikou K; Tamburini E; Scartozzi M; Cascinu S
Clin Colorectal Cancer; 2020 Jun; 19(2):82-90.e9. PubMed ID: 32192883
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
Abrahao ABK; Ko YJ; Berry S; Chan KKW
Clin Colorectal Cancer; 2018 Jun; 17(2):113-120. PubMed ID: 29174481
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
Walter T; Hawkins NS; Pollock RF; Colaone F; Shergill S; Ross PJ
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2575-2587. PubMed ID: 32715436
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Murgioni S; Rossini D; Marmorino F; Mennitto A; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
Ann Oncol; 2017 May; 28(5):1015-1022. PubMed ID: 28453695
[TBL] [Abstract][Full Text] [Related]
11. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review.
Wu Y; Fan Y; Dong D; Dong X; Hu Y; Shi Y; Jing J; Li E
Ther Adv Med Oncol; 2020; 12():1758835920940932. PubMed ID: 32728393
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
[TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.
Cao M; Zhou M; Zhang J
J Chemother; 2020 Jul; 32(4):163-170. PubMed ID: 32081104
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer.
Gao Z; Cao C; Bao Y; Fan Y; Chen G; Fu P
Technol Cancer Res Treat; 2020; 19():1533033820943241. PubMed ID: 32914703
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
[TBL] [Abstract][Full Text] [Related]
17. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Dadduzio V; Salvatore L; Borelli B; Pietrantonio F; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
Eur J Cancer; 2017 Nov; 86():197-206. PubMed ID: 28992563
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
Masuishi T; Taniguchi H; Hamauchi S; Komori A; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
Clin Colorectal Cancer; 2017 Jun; 16(2):e15-e22. PubMed ID: 27670892
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
Arita S; Shirakawa T; Matsushita Y; Shimokawa HK; Hirano G; Makiyama A; Shibata Y; Tamura S; Esaki T; Mitsugi K; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2016 Apr; 36(4):1959-66. PubMed ID: 27069187
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
Vitale P; Zanaletti N; Famiglietti V; De Falco V; Cervantes A; Rosellò S; Fenocchio E; Milanesio M; Lombardi P; Ciardiello D; Martini G; Martinelli E; Ciardiello F; Troiani T; Napolitano S
Clin Colorectal Cancer; 2021 Sep; 20(3):227-235. PubMed ID: 34226142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
